Floatz logo

Irinotecan

Clinical Stage IV Cutaneous Melanoma AJCC v8

GI Innovation, Inc.Small moleculePhase 2Active
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Clinical Stage IV Cutaneous Melanoma AJCC v8 cohort.

Asset / SponsorPhaseRating
Ipilimumab
Amsterdam UMC, location VUmc
Phase 3BB
Binimetinib
Leiden University Medical Center
Phase 3BB
Epirubicin
Aminex Therapeutics, Inc.
Phase 3BB
Nivolumab
Fred Hutchinson Cancer Center
Phase 3BB
Dabrafenib
Immuneering Corporation
Phase 3BB

View all 18 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →